1 Min Read
May 1 (Reuters) - AstraZeneca
* Says average wholesale acquisition cost of durvalumab around $15,000/month, following FDA approval of drug for bladder cancer Further company coverage: (Reporting by UK bureau)
All quotes delayed a minimum of 15 minutes. See here for a complete list of exchanges and delays.
© 2017 Reuters. All Rights Reserved.